Tilray Brands, Inc (TLRY)

$1.84

+0.12

(+6.98%)▲

Market is closed - opens 7 PM, 24 Apr 2024

Insights on Tilray Brands, Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 193.77M → 188.34M (in $), with an average decrease of 2.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -49.00M → -92.70M (in $), with an average decrease of 89.2% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 35.3% return, outperforming this stock by 57.0%

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 44.8% return, outperforming this stock by 135.8%

Performance

  • $1.71
    $1.87
    $1.84
    downward going graph

    6.86%

    Downside

    Day's Volatility :8.35%

    Upside

    1.6%

    downward going graph
  • $1.50
    $3.40
    $1.84
    downward going graph

    18.48%

    Downside

    52 Weeks Volatility :55.88%

    Upside

    45.88%

    downward going graph

Returns

PeriodTilray Brands, IncSector (Health Care)Index (Russel 2000)
3 Months
-12.69%
1.9%
0.0%
6 Months
-4.66%
10.7%
0.0%
1 Year
-21.7%
4.6%
-1.1%
3 Years
-91.36%
14.2%
-22.1%

Highlights

Market Capitalization
1.3B
Book Value
$4.34
Earnings Per Share (EPS)
-0.44
Wall Street Target Price
2.36
Profit Margin
-47.35%
Operating Margin TTM
-16.54%
Return On Assets TTM
-1.67%
Return On Equity TTM
-9.69%
Revenue TTM
743.2M
Revenue Per Share TTM
1.04
Quarterly Revenue Growth YOY
29.4%
Gross Profit TTM
116.8M
EBITDA
9.7M
Diluted Eps TTM
-0.44
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.31
EPS Estimate Next Year
-0.1
EPS Estimate Current Quarter
-0.07
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Hold
    40%Buy
    59%Hold
    0
    0%Sell
Based on 22 Wall street analysts offering stock ratings for Tilray Brands, Inc(by analysts ranked 0 to 5 stars)
Based on 22 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
13
13
13
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 28.26%

Current $1.84
Target $2.36

Company Financials

FY18Y/Y Change
Revenue
175.2M
↑ 512.12%
Net Income
-12.2M
↓ 153.4%
Net Profit Margin
-6.96%
↓ 86.73%
FY19Y/Y Change
Revenue
391.0M
↑ 123.11%
Net Income
-61.0M
↑ 400.36%
Net Profit Margin
-15.61%
↓ 8.65%
FY20Y/Y Change
Revenue
391.0M
↑ 0.0%
Net Income
-61.0M
↑ 0.0%
Net Profit Margin
-15.61%
↑ 0.0%
FY21Y/Y Change
Revenue
513.1M
↑ 31.23%
Net Income
-336.0M
↑ 450.69%
Net Profit Margin
-65.49%
↓ 49.88%
FY22Y/Y Change
Revenue
628.4M
↑ 22.47%
Net Income
-434.1M
↑ 29.2%
Net Profit Margin
-69.09%
↓ 3.6%
FY23Y/Y Change
Revenue
627.1M
↓ 0.2%
Net Income
-1.4B
↑ 232.39%
Net Profit Margin
-230.1%
↓ 161.01%
Q4 FY22Q/Q Change
Revenue
144.1M
↓ 5.92%
Net Income
-61.6M
↓ 6.32%
Net Profit Margin
-42.76%
↑ 0.18%
Q1 FY23Q/Q Change
Revenue
145.6M
↑ 1.01%
Net Income
-1.2B
↑ 1840.05%
Net Profit Margin
-821.32%
↓ 778.56%
Q2 FY23Q/Q Change
Revenue
184.2M
↑ 26.51%
Net Income
-119.8M
↓ 89.98%
Net Profit Margin
-65.05%
↑ 756.27%
Q3 FY23Q/Q Change
Revenue
176.9M
↓ 3.93%
Net Income
-55.9M
↓ 53.38%
Net Profit Margin
-31.57%
↑ 33.48%
Q4 FY23Q/Q Change
Revenue
193.8M
↑ 9.51%
Net Income
-49.0M
↓ 12.27%
Net Profit Margin
-25.29%
↑ 6.28%
Q1 FY24Q/Q Change
Revenue
188.3M
↓ 2.8%
Net Income
-92.7M
↑ 89.15%
Net Profit Margin
-49.22%
↓ 23.93%
FY18Y/Y Change
Total Assets
1.8B
↑ 77.08%
Total Liabilities
523.6M
↑ 380.55%
FY19Y/Y Change
Total Assets
1.8B
↓ 0.19%
Total Liabilities
475.9M
↓ 9.11%
FY20Y/Y Change
Total Assets
1.8B
↑ 0.0%
Total Liabilities
475.9M
↑ 0.0%
FY21Y/Y Change
Total Assets
6.0B
↑ 234.51%
Total Liabilities
1.6B
↑ 227.82%
FY22Y/Y Change
Total Assets
5.4B
↓ 9.55%
Total Liabilities
1.0B
↓ 35.37%
FY23Y/Y Change
Total Assets
4.3B
↓ 20.96%
Total Liabilities
977.3M
↓ 3.08%
Q4 FY22Q/Q Change
Total Assets
5.5B
↓ 2.11%
Total Liabilities
991.2M
↓ 3.7%
Q1 FY23Q/Q Change
Total Assets
4.4B
↓ 20.07%
Total Liabilities
969.1M
↓ 2.23%
Q2 FY23Q/Q Change
Total Assets
4.3B
↓ 1.57%
Total Liabilities
977.3M
↑ 0.84%
Q3 FY23Q/Q Change
Total Assets
4.4B
↑ 2.21%
Total Liabilities
1.0B
↑ 2.39%
Q4 FY23Q/Q Change
Total Assets
4.3B
↓ 1.63%
Total Liabilities
937.2M
↓ 6.34%
Q1 FY24Q/Q Change
Total Assets
4.2B
↓ 2.72%
Total Liabilities
869.8M
↓ 7.19%
FY18Y/Y Change
Operating Cash Flow
-41.1M
↑ 838.11%
Investing Cash Flow
-98.6M
↓ 55.35%
Financing Cash Flow
535.5M
↑ 234.65%
FY19Y/Y Change
Operating Cash Flow
-96.4M
↑ 134.64%
Investing Cash Flow
-253.2M
↑ 156.72%
Financing Cash Flow
125.4M
↓ 76.58%
FY20Y/Y Change
Operating Cash Flow
-96.4M
↑ 0.0%
Investing Cash Flow
-41.7M
↓ 83.54%
Financing Cash Flow
125.4M
↑ 0.0%
FY21Y/Y Change
Operating Cash Flow
-44.7M
↓ 53.63%
Investing Cash Flow
-21.5M
↓ 48.34%
Financing Cash Flow
124.3M
↓ 0.87%
Q4 FY22Q/Q Change
Operating Cash Flow
29.2M
↓ 163.13%
Investing Cash Flow
-4.6M
↓ 98.31%
Financing Cash Flow
-57.3M
↓ 146.32%
Q1 FY23Q/Q Change
Operating Cash Flow
-18.6M
↓ 163.79%
Investing Cash Flow
-26.3M
↑ 472.52%
Financing Cash Flow
-2.4M
↓ 95.73%
Q2 FY23Q/Q Change
Operating Cash Flow
43.6M
↓ 334.0%
Investing Cash Flow
-26.3M
↑ 0.0%
Financing Cash Flow
6.2M
↓ 355.36%

Technicals Summary

Sell

Neutral

Buy

Tilray Brands, Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Tilray Brands, Inc
Tilray Brands, Inc
-14.42%
-4.66%
-21.7%
-91.36%
-96.99%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-0.11%
28.23%
35.27%
41.85%
77.04%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-0.24%
1.82%
-5.93%
13.5%
13.5%
Zoetis Inc.
Zoetis Inc.
-10.88%
-10.51%
-15.19%
-11.92%
47.93%
Viatris Inc.
Viatris Inc.
-3.97%
24.7%
21.76%
-16.16%
-30.48%
Catalent, Inc.
Catalent, Inc.
-0.66%
31.9%
24.68%
-51.57%
26.05%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Tilray Brands, Inc
Tilray Brands, Inc
6.93
NA
NA
-0.31
-0.1
-0.02
NA
4.34
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
53.44
53.44
0.44
4.78
0.13
0.09
NA
22.61
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.86
29.86
1.69
0.45
0.07
0.04
0.03
1.8
Zoetis Inc.
Zoetis Inc.
28.76
28.76
2.58
5.8
0.5
0.13
0.01
10.9
Viatris Inc.
Viatris Inc.
225.0
225.0
NA
2.78
0.0
0.03
0.04
17.05
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.48
-0.3
-0.01
NA
20.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Tilray Brands, Inc
Tilray Brands, Inc
Hold
$1.3B
-96.99%
6.93
-47.35%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$13.3B
77.04%
53.44
13.23%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.2B
13.5%
29.86
9.28%
Zoetis Inc.
Zoetis Inc.
Buy
$66.5B
47.93%
28.76
27.43%
Viatris Inc.
Viatris Inc.
Hold
$13.4B
-30.48%
225.0
0.35%
Catalent, Inc.
Catalent, Inc.
Hold
$10.1B
26.05%
211.02
-31.77%

Institutional Holdings

    Company Information

    tilray is a global leader in medical cannabis research and production dedicated to providing safe, consistent and reliable therapy to patients. we are the only gmp certified medical cannabis producer currently supplying products to thousands of patients, physicians, pharmacies, hospitals, governments and researchers in australia, canada, the european union and the americas.

    Organization
    Tilray Brands, Inc
    Employees
    1600
    CEO
    Mr. Irwin David Simon
    Industry
    Health Technology

    Discover More

    FAQs